Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Current Deferred Revenue (2016 - 2018)

VYNE Therapeutics (VYNE) has disclosed Current Deferred Revenue for 3 consecutive years, with $1.8 million as the latest value for Q1 2018.

  • For the quarter ending Q1 2018, Current Deferred Revenue changed N/A year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Mar 2018, changed N/A, and an annual FY2017 reading of $1.8 million, changed 0.0% over the prior year.
  • Current Deferred Revenue was $1.8 million for Q1 2018 at VYNE Therapeutics, roughly flat from $1.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.8 million in Q4 2016 and bottomed at $1.8 million in Q4 2016.
  • Average Current Deferred Revenue over 3 years is $1.8 million, with a median of $1.8 million recorded in 2016.
  • Peak annual rise in Current Deferred Revenue hit 0.0% in 2017, while the deepest fall reached 0.0% in 2017.
  • Year by year, Current Deferred Revenue stood at $1.8 million in 2016, then changed by 0.0% to $1.8 million in 2017, then changed by 0.0% to $1.8 million in 2018.
  • Business Quant data shows Current Deferred Revenue for VYNE at $1.8 million in Q1 2018, $1.8 million in Q4 2017, and $1.8 million in Q4 2016.